TY - JOUR
T1 - Ontogenic changes in hematopoietic hierarchy determine pediatric specificity and disease phenotype in fusion oncogene– driven myeloid leukemia
AU - Lopez, Cécile K.
AU - Noguera, Esteve
AU - Stavropoulou, Vaia
AU - Robert, Elie
AU - Aid, Zakia
AU - Ballerini, Paola
AU - Bilhou-Nabera, Chrystèle
AU - Lapillonne, Hélène
AU - Boudia, Fabien
AU - Thirant, Cécile
AU - Fagnan, Alexandre
AU - Arcangeli, Marie Laure
AU - Kinston, Sarah J.
AU - Diop, M’Boyba
AU - Job, Bastien
AU - Lecluse, Yann
AU - Brunet, Erika
AU - Babin, Loélia
AU - Villeval, Jean Luc
AU - Delabesse, Eric
AU - Peters, Antoine H.F.M.
AU - Vainchenker, William
AU - Gaudry, Muriel
AU - Masetti, Riccardo
AU - Locatelli, Franco
AU - Malinge, Sébastien
AU - Nerlov, Claus
AU - Droin, Nathalie
AU - Lobry, Camille
AU - Godin, Isabelle
AU - Bernard, Olivier A.
AU - Göttgens, Berthold
AU - Petit, Arnaud
AU - Pflumio, Françoise
AU - Schwaller, Juerg
AU - Mercher, Thomas
N1 - Publisher Copyright:
© 2019 American Association for Cancer Research.
PY - 2019/12/1
Y1 - 2019/12/1
N2 - Fusion oncogenes are prevalent in several pediatric cancers, yet little is known about the specific associations between age and phenotype. We observed that fusion oncogenes, such as ETO2–GLIS2, are associated with acute megakaryoblastic or other myeloid leukemia subtypes in an age-dependent manner. Analysis of a novel inducible transgenic mouse model showed that ETO2–GLIS2 expression in fetal hematopoietic stem cells induced rapid megakaryoblastic leukemia whereas expression in adult bone marrow hematopoietic stem cells resulted in a shift toward myeloid transformation with a strikingly delayed in vivo leukemogenic potential. Chromatin accessibility and single-cell transcriptome analyses indicate ontogeny-dependent intrinsic and ETO2–GLIS2-induced differences in the activities of key transcription factors, including ERG, SPI1, GATA1, and CEBPA. Importantly, switching off the fusion oncogene restored terminal differentiation of the leukemic blasts. Together, these data show that aggressiveness and phenotypes in pediatric acute myeloid leukemia result from an ontogeny-related differential susceptibility to transformation by fusion oncogenes. SIGNIFICANCE: This work demonstrates that the clinical phenotype of pediatric acute myeloid leukemia is determined by ontogeny-dependent susceptibility for transformation by oncogenic fusion genes. The phenotype is maintained by potentially reversible alteration of key transcription factors, indicating that targeting of the fusions may overcome the differentiation blockage and revert the leukemic state.
AB - Fusion oncogenes are prevalent in several pediatric cancers, yet little is known about the specific associations between age and phenotype. We observed that fusion oncogenes, such as ETO2–GLIS2, are associated with acute megakaryoblastic or other myeloid leukemia subtypes in an age-dependent manner. Analysis of a novel inducible transgenic mouse model showed that ETO2–GLIS2 expression in fetal hematopoietic stem cells induced rapid megakaryoblastic leukemia whereas expression in adult bone marrow hematopoietic stem cells resulted in a shift toward myeloid transformation with a strikingly delayed in vivo leukemogenic potential. Chromatin accessibility and single-cell transcriptome analyses indicate ontogeny-dependent intrinsic and ETO2–GLIS2-induced differences in the activities of key transcription factors, including ERG, SPI1, GATA1, and CEBPA. Importantly, switching off the fusion oncogene restored terminal differentiation of the leukemic blasts. Together, these data show that aggressiveness and phenotypes in pediatric acute myeloid leukemia result from an ontogeny-related differential susceptibility to transformation by fusion oncogenes. SIGNIFICANCE: This work demonstrates that the clinical phenotype of pediatric acute myeloid leukemia is determined by ontogeny-dependent susceptibility for transformation by oncogenic fusion genes. The phenotype is maintained by potentially reversible alteration of key transcription factors, indicating that targeting of the fusions may overcome the differentiation blockage and revert the leukemic state.
UR - http://www.scopus.com/inward/record.url?scp=85075962611&partnerID=8YFLogxK
U2 - 10.1158/2159-8290.CD-18-1463
DO - 10.1158/2159-8290.CD-18-1463
M3 - Article
C2 - 31662298
AN - SCOPUS:85075962611
SN - 2159-8274
VL - 9
SP - 1736
EP - 1753
JO - Cancer Discovery
JF - Cancer Discovery
IS - 12
ER -